"Das Rotkreuzklinikum München ist ein Haus der Schwerpunktversorgung und Akademisches Lehrkrankenhaus der Technischen Universität München. Es liegt in zentraler Lage im Stadtteil Neuhausen-Gern am Standort Nymphenburger Straße und verfügt über 435 Betten in den Fachabteilungen für Chirurgie, Orthopädie, Urologie, Innere Medizin, HNO und Augenheilkunde."

During the past decade, Rotkreuzklinikum München conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 10 clinical trials were completed, i.e. on average, 52.6% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 6 clinical trials were completed. i.e. 54.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rotkreuzklinikum München" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "AGO Research GmbH" with 3 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "German Breast Group" with 2 trials sponsored and "Alliance for Clinical Trials in Oncology" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rotkreuzklinikum München" #1 collaborator was "Breast International Group" with 3 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 2 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Rotkreuzklinikum München" are "Breast Cancer" (8 trials), "Seminoma" (2 trials), "Triple Negative Breast Cancer" (2 trials), "Breast Diseases" (1 trials) and "Breast Neoplasm" (1 trials). Many other conditions were trialed in "Rotkreuzklinikum München" in a lesser frequency.

Most popular intervention types in "Rotkreuzklinikum München" are "Drug" (26 trials), "Other" (2 trials), "Procedure" (2 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (7 trials), "Paclitaxel" (6 trials), "Placebo" (5 trials), "Trastuzumab" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Rotkreuzklinikum München" are 14 trials for "All" genders, 12 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Rotkreuzklinikum München". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Rotkreuzklinikum München, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Rotkreuzklinikum München, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".